P/E ratio for BioCryst Pharmaceuticals (BCRX)
P/E ratio as of April 2024 (TTM): -3.33
According to BioCryst Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.332. At the end of 2022 the company had a P/E ratio of -8.63.
P/E ratio history for BioCryst Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -8.63 | -35.81% |
| 2021 | -13.4 | 94.93% |
| 2020 | -6.90 | 95.95% |
| 2019 | -3.52 | -57.25% |
| 2018 | -8.23 | 30.82% |
| 2017 | -6.29 | -25.42% |
| 2016 | -8.44 | -51.75% |
| 2015 | -17.5 | -2.19% |
| 2014 | -17.9 | 29.41% |
| 2013 | -13.8 | 668.76% |
| 2012 | -1.80 | -8.31% |
| 2011 | -1.96 | -71.18% |
| 2010 | -6.80 | -63.14% |
| 2009 | -18.5 | 775.7% |
| 2008 | -2.11 | -69.65% |
| 2007 | -6.94 | -9.9% |
| 2006 | -7.71 | -53.53% |
| 2005 | -16.6 | 186.92% |
| 2004 | -5.78 | -39.25% |
| 2003 | -9.51 | 851.39% |
| 2002 | -1.0000 | -92.68% |
| 2001 | -13.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 14.9 | -547.21% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.8 | -453.00% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | -16.5 | 394.45% | 🇺🇸 USA |
 Repligen
RGEN | 79.8 | -2,494.35% | 🇺🇸 USA |
 Novavax NVAX | -0.5685 | -82.94% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -15.1 | 353.93% | 🇺🇸 USA |
 NanoViricides NNVC | -1.86 | -44.05% | 🇺🇸 USA |
 Cel-Sci
CVM | -1.86 | -44.26% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | -0.1589 | -95.23% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.